| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.009 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.01 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | 0.16 | 0.01 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.095 | 0.01 |
| mRNA | Roscovitine | FIMM | pan-cancer | AAC | 0.41 | 0.01 |
| mRNA | austocystin d | CTRPv2 | pan-cancer | AAC | -0.093 | 0.01 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.18 | 0.01 |
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.083 | 0.01 |